|
Fragment-based drug discovery truly unlocks synergy of parts by finding highly diverse and rather small ligands that ever increase their binding efficiency and maximize bioavailability once joined in a new molecule. FBDD is also great compliment to any HTS campaign for enzyme targets as it aids early hit discovery and optimization when data from both screening approaches is compared. Fragment library screen is always target specific in fit being comprised of minimum pharmacophores. FBDD “combines the empiricism of random screening with the rationality of structure-based design”. If available, any structural parts match between HST and FBDD hits is good foundation for preliminary SAR. TimTec Fragment-Based Library, FBL gathers structurally diverse ligands with low molecular weight and high solubility.
TimTec Fragment-Based Library, FBL, Criteria:
*All calculations are performed using TimTec proprietary software ChemDBsoft Compounds can be delivered in dry form in custom milligram or micromolar amounts and as freshly prepared DMSO solution aliquots.
Contact TimTec today to discover your “powerful” weak inhibitors!Fragment-Based Drug Discovery has been gaining more and more attention since mid 1990s, the year when the SAR-by-MNMR technology is developed at Abbott. Number of most recent technological advancements makes FBDD approachable part of HTS campaigns. Comparison Chart
Vernalis classification: the strength and limitations of various experimental approaches. GEN. March 2009, Vol 29, 5, 22-24 Small in size FBDD libraries furnish vast chemical space design combinations in building drugs from small molecular pieces. Structure-based approach can be applied very early in fragments optimization to decrease and/or eliminate undesirable structural characteristics to boost in vivo safety and minimize number of synthesized lead candidates. Various methods for the identification, structural analysis, and optimization of fragment leads. Am Drug Disc. Feb/March 2008, Vol 3, 2, pp 56-60
FBDD complementary benefits to HTS:
Reference: Jahnke, W., Erlanson, D. A. (Eds.), (2006). Fragment-based approaches in drug discovery. Weinheim, Germany: Wiley-VCH. Barker J., et. al. Integrating HTS and fragment-based drug discovery. Drug Discovery World. Summer 2008; Vol 9, 3, pp.69-75 Sun C., Hajduk P.J. How Then Shall We Screen? American Drug Discovery. Feb/March 2008, Vol 3, 2, pp 56-60 Gitig D. Revitalizig Surface Plasmon Resonance. Resurgence is Drivenby SPR’s Aptitude for Fragment-Based Lead Discovery. GEN. March 2009, Vol 29, 5, 22-24 Liszewski K. Capitalizing on Fragment-Based Discovery. Computational and Medicinal Chemists are Joining Forces to Turn Hits into Leads. GEN. April, 2009, Vol. 29, 8, 18-22 Boettcher A., et.al. Fragment-Based Screening by Biochemical Assays Systematic Feasibility Studies with Trypsin and MMP12. Sept 20, 2010, vol. 15 no. 9, p 1029-1041
Unlock synergy of parts!
|
